Iqvia Holdings Inc.
IQVIA Reports Second-Quarter 2024 Financial Results
Summary
IQVIA Holdings Inc. announced its financial results for the second quarter of 2024. The company reported revenue of $3,814 million, GAAP Net Income of $363 million, and Adjusted EBITDA of $887 million. IQVIA's R&D Solutions segment saw a 3.5% increase in revenue year-over-year, driving strong bookings and backlog growth. The company updated its full-year 2024 guidance, projecting revenue between $15,425 million and $15,525 million, Adjusted EBITDA between $3,705 million and $3,765 million, and Adjusted Diluted Earnings per Share between $11.10 and $11.30.
Profitelligence Alerts
Get alerts for IQV
Be first to know when Iqvia Holdings Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Iqvia Holdings Inc.
Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.
Official SEC Documents
Advertisement